Matches in SemOpenAlex for { <https://semopenalex.org/work/W61193775> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W61193775 endingPage "43" @default.
- W61193775 startingPage "1133" @default.
- W61193775 abstract "Indoleamine 2,3-dioxygenase (IDO) catalyses tryptophan degradation in the kynurenine pathway, and plays an important role in immune tolerance by regulating antigen-presenting cells. We introduce the results of our investigations of IDO for hematological malignancies. Serum L-kynurenine (KYN) for diffuse large B cell lymphoma (DLBCL): The Complete remission (CR) rates of patients with lower KYN and higher KYN were 83% and 61%, respectively (p < 0.05). The 3-year overall survival (OS) rates for patients with lower KYN and higher KYN were 89% and 58%, respectively (p < 0.005). IDO expression for DLBCL: CR rates in patients with IDO-positive DLBCL and IDO-negative DLBCL were 55.3% and 79.0% (p = 0.008), while 3-year overall survival rates were 49.8% and 78.8%, respectively (p = 0.0003). Serum KYN and IDO expression for DLBCL: Three-year OS rates were 55% and 78% for patients with higher KYN and lower KYN, respectively (p = 0.027), and 44% and 75% for patients with IDO-positive and IDO-negative DLBCL, respectively (p = 0.0017). Patients with low KYN and IDO-negative showed the best outcomes, while patients with high KYN and IDO-positive showed the poorest outcome. Serum KYN for T-cell lymphoma: The 5-year OS rates for patients with lower KYN and higher KYN were 77% and 38%, respectively (p < 0.005). Serum KYN and IDO expression for AML: The 5-year OS rates for patients with lower KYN and higher KYN were 68% and 11%, respectively (p < 0.05). The 5-year OS rates for patients with IDO mRNA expression and without IDO mRNA expression were 64% and 41%, respectively (p < 0.05). IDO activity might play an important role in the disease activity of hematological malignancies." @default.
- W61193775 created "2016-06-24" @default.
- W61193775 creator A5030791716 @default.
- W61193775 creator A5090297441 @default.
- W61193775 date "2011-12-01" @default.
- W61193775 modified "2023-09-23" @default.
- W61193775 title "[Indoleamine 2, 3-dioxygenasase (IDO) as a prognostic factor of hematological malignancies]." @default.
- W61193775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22338916" @default.
- W61193775 hasPublicationYear "2011" @default.
- W61193775 type Work @default.
- W61193775 sameAs 61193775 @default.
- W61193775 citedByCount "2" @default.
- W61193775 countsByYear W611937752015 @default.
- W61193775 crossrefType "journal-article" @default.
- W61193775 hasAuthorship W61193775A5030791716 @default.
- W61193775 hasAuthorship W61193775A5090297441 @default.
- W61193775 hasConcept C126322002 @default.
- W61193775 hasConcept C203014093 @default.
- W61193775 hasConcept C2776706248 @default.
- W61193775 hasConcept C2776710720 @default.
- W61193775 hasConcept C2777503454 @default.
- W61193775 hasConcept C2778559949 @default.
- W61193775 hasConcept C2779338263 @default.
- W61193775 hasConcept C515207424 @default.
- W61193775 hasConcept C55493867 @default.
- W61193775 hasConcept C71924100 @default.
- W61193775 hasConcept C83478079 @default.
- W61193775 hasConcept C86803240 @default.
- W61193775 hasConcept C90924648 @default.
- W61193775 hasConceptScore W61193775C126322002 @default.
- W61193775 hasConceptScore W61193775C203014093 @default.
- W61193775 hasConceptScore W61193775C2776706248 @default.
- W61193775 hasConceptScore W61193775C2776710720 @default.
- W61193775 hasConceptScore W61193775C2777503454 @default.
- W61193775 hasConceptScore W61193775C2778559949 @default.
- W61193775 hasConceptScore W61193775C2779338263 @default.
- W61193775 hasConceptScore W61193775C515207424 @default.
- W61193775 hasConceptScore W61193775C55493867 @default.
- W61193775 hasConceptScore W61193775C71924100 @default.
- W61193775 hasConceptScore W61193775C83478079 @default.
- W61193775 hasConceptScore W61193775C86803240 @default.
- W61193775 hasConceptScore W61193775C90924648 @default.
- W61193775 hasIssue "12" @default.
- W61193775 hasLocation W611937751 @default.
- W61193775 hasOpenAccess W61193775 @default.
- W61193775 hasPrimaryLocation W611937751 @default.
- W61193775 hasRelatedWork W1979638357 @default.
- W61193775 hasRelatedWork W2008878335 @default.
- W61193775 hasRelatedWork W2042454390 @default.
- W61193775 hasRelatedWork W2090012912 @default.
- W61193775 hasRelatedWork W2171137688 @default.
- W61193775 hasRelatedWork W2565640784 @default.
- W61193775 hasRelatedWork W2573678978 @default.
- W61193775 hasRelatedWork W2591210386 @default.
- W61193775 hasRelatedWork W3200752118 @default.
- W61193775 hasRelatedWork W61193775 @default.
- W61193775 hasVolume "59" @default.
- W61193775 isParatext "false" @default.
- W61193775 isRetracted "false" @default.
- W61193775 magId "61193775" @default.
- W61193775 workType "article" @default.